Eintrag weiter verarbeiten
Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist
Gespeichert in:
| Zeitschriftentitel: | Molecular Cancer Therapeutics |
|---|---|
| Personen und Körperschaften: | , , , , , , |
| In: | Molecular Cancer Therapeutics, 11, 2012, 11, S. 2541-2546 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Association for Cancer Research (AACR)
|
| Schlagwörter: |
| author_facet |
Subbiah, Vivek Brown, Robert E. Buryanek, Jamie Trent, Jonathan Ashkenazi, Avi Herbst, Roy Kurzrock, Razelle Subbiah, Vivek Brown, Robert E. Buryanek, Jamie Trent, Jonathan Ashkenazi, Avi Herbst, Roy Kurzrock, Razelle |
|---|---|
| author |
Subbiah, Vivek Brown, Robert E. Buryanek, Jamie Trent, Jonathan Ashkenazi, Avi Herbst, Roy Kurzrock, Razelle |
| spellingShingle |
Subbiah, Vivek Brown, Robert E. Buryanek, Jamie Trent, Jonathan Ashkenazi, Avi Herbst, Roy Kurzrock, Razelle Molecular Cancer Therapeutics Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist Cancer Research Oncology |
| author_sort |
subbiah, vivek |
| spelling |
Subbiah, Vivek Brown, Robert E. Buryanek, Jamie Trent, Jonathan Ashkenazi, Avi Herbst, Roy Kurzrock, Razelle 1535-7163 1538-8514 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/1535-7163.mct-12-0358 <jats:title>Abstract</jats:title> <jats:p>Recombinant human Apo2L/TRAIL (dulanermin) is based on the ligand for death receptors (DR4 and DR5), which promotes apoptosis. We report a patient with refractory chondrosarcoma who showed a prolonged response to dulanermin and explore mechanisms of response and resistance. This heavily pretreated patient had progressive metastatic chondrosarcoma to the lung. On dulanermin (8 mg/kg i.v. on days 1–5 in a 21-day cycle), the patient achieved a sustained partial response with only subcentimeter nodules remaining. After 62 months of dulanermin treatment, progressive disease in the lungs was noted, and the patient underwent a resection that confirmed chondrosarcoma. DR4 was detected (immunohistochemistry) in the patient's tumor, which may have enabled the response. However, upregulation of prosurvival proteins, namely, phosphorylated (p)-NF-κBp65 (Ser 536), p-STAT3 (Tyr 705), p-ERK 1/2 (Thr 202/Tyr 204), p-mTOR (Ser 2448), FASN, and Bcl-2, were also detected, which may have provided the underlying mechanisms for acquired dulanermin resistance. The patient was restarted on dulanermin and has continued on this treatment for an additional 16 months since surgery (78 months since initiation of treatment), with his most recent computed tomography (CT) scans showing no evidence of disease. Mol Cancer Ther; 11(11); 2541–6. ©2012 AACR.</jats:p> Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist Molecular Cancer Therapeutics |
| doi_str_mv |
10.1158/1535-7163.mct-12-0358 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xNTM1LTcxNjMubWN0LTEyLTAzNTg |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xNTM1LTcxNjMubWN0LTEyLTAzNTg |
| institution |
DE-D161 DE-Zwi2 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 |
| imprint |
American Association for Cancer Research (AACR), 2012 |
| imprint_str_mv |
American Association for Cancer Research (AACR), 2012 |
| issn |
1535-7163 1538-8514 |
| issn_str_mv |
1535-7163 1538-8514 |
| language |
English |
| mega_collection |
American Association for Cancer Research (AACR) (CrossRef) |
| match_str |
subbiah2012targetingtheapoptoticpathwayinchondrosarcomausingrecombinanthumanapo2ltraildulanerminadualproapoptoticreceptordr4dr5agonist |
| publishDateSort |
2012 |
| publisher |
American Association for Cancer Research (AACR) |
| recordtype |
ai |
| record_format |
ai |
| series |
Molecular Cancer Therapeutics |
| source_id |
49 |
| title |
Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist |
| title_unstemmed |
Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist |
| title_full |
Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist |
| title_fullStr |
Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist |
| title_full_unstemmed |
Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist |
| title_short |
Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist |
| title_sort |
targeting the apoptotic pathway in chondrosarcoma using recombinant human apo2l/trail (dulanermin), a dual proapoptotic receptor (dr4/dr5) agonist |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1158/1535-7163.mct-12-0358 |
| publishDate |
2012 |
| physical |
2541-2546 |
| description |
<jats:title>Abstract</jats:title>
<jats:p>Recombinant human Apo2L/TRAIL (dulanermin) is based on the ligand for death receptors (DR4 and DR5), which promotes apoptosis. We report a patient with refractory chondrosarcoma who showed a prolonged response to dulanermin and explore mechanisms of response and resistance. This heavily pretreated patient had progressive metastatic chondrosarcoma to the lung. On dulanermin (8 mg/kg i.v. on days 1–5 in a 21-day cycle), the patient achieved a sustained partial response with only subcentimeter nodules remaining. After 62 months of dulanermin treatment, progressive disease in the lungs was noted, and the patient underwent a resection that confirmed chondrosarcoma. DR4 was detected (immunohistochemistry) in the patient's tumor, which may have enabled the response. However, upregulation of prosurvival proteins, namely, phosphorylated (p)-NF-κBp65 (Ser 536), p-STAT3 (Tyr 705), p-ERK 1/2 (Thr 202/Tyr 204), p-mTOR (Ser 2448), FASN, and Bcl-2, were also detected, which may have provided the underlying mechanisms for acquired dulanermin resistance. The patient was restarted on dulanermin and has continued on this treatment for an additional 16 months since surgery (78 months since initiation of treatment), with his most recent computed tomography (CT) scans showing no evidence of disease. Mol Cancer Ther; 11(11); 2541–6. ©2012 AACR.</jats:p> |
| container_issue |
11 |
| container_start_page |
2541 |
| container_title |
Molecular Cancer Therapeutics |
| container_volume |
11 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792344820646150154 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T17:13:41.148Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Targeting+the+Apoptotic+Pathway+in+Chondrosarcoma+Using+Recombinant+Human+Apo2L%2FTRAIL+%28Dulanermin%29%2C+a+Dual+Proapoptotic+Receptor+%28DR4%2FDR5%29+Agonist&rft.date=2012-11-01&genre=article&issn=1538-8514&volume=11&issue=11&spage=2541&epage=2546&pages=2541-2546&jtitle=Molecular+Cancer+Therapeutics&atitle=Targeting+the+Apoptotic+Pathway+in+Chondrosarcoma+Using+Recombinant+Human+Apo2L%2FTRAIL+%28Dulanermin%29%2C+a+Dual+Proapoptotic+Receptor+%28DR4%2FDR5%29+Agonist&aulast=Kurzrock&aufirst=Razelle&rft_id=info%3Adoi%2F10.1158%2F1535-7163.mct-12-0358&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792344820646150154 |
| author | Subbiah, Vivek, Brown, Robert E., Buryanek, Jamie, Trent, Jonathan, Ashkenazi, Avi, Herbst, Roy, Kurzrock, Razelle |
| author_facet | Subbiah, Vivek, Brown, Robert E., Buryanek, Jamie, Trent, Jonathan, Ashkenazi, Avi, Herbst, Roy, Kurzrock, Razelle, Subbiah, Vivek, Brown, Robert E., Buryanek, Jamie, Trent, Jonathan, Ashkenazi, Avi, Herbst, Roy, Kurzrock, Razelle |
| author_sort | subbiah, vivek |
| container_issue | 11 |
| container_start_page | 2541 |
| container_title | Molecular Cancer Therapeutics |
| container_volume | 11 |
| description | <jats:title>Abstract</jats:title> <jats:p>Recombinant human Apo2L/TRAIL (dulanermin) is based on the ligand for death receptors (DR4 and DR5), which promotes apoptosis. We report a patient with refractory chondrosarcoma who showed a prolonged response to dulanermin and explore mechanisms of response and resistance. This heavily pretreated patient had progressive metastatic chondrosarcoma to the lung. On dulanermin (8 mg/kg i.v. on days 1–5 in a 21-day cycle), the patient achieved a sustained partial response with only subcentimeter nodules remaining. After 62 months of dulanermin treatment, progressive disease in the lungs was noted, and the patient underwent a resection that confirmed chondrosarcoma. DR4 was detected (immunohistochemistry) in the patient's tumor, which may have enabled the response. However, upregulation of prosurvival proteins, namely, phosphorylated (p)-NF-κBp65 (Ser 536), p-STAT3 (Tyr 705), p-ERK 1/2 (Thr 202/Tyr 204), p-mTOR (Ser 2448), FASN, and Bcl-2, were also detected, which may have provided the underlying mechanisms for acquired dulanermin resistance. The patient was restarted on dulanermin and has continued on this treatment for an additional 16 months since surgery (78 months since initiation of treatment), with his most recent computed tomography (CT) scans showing no evidence of disease. Mol Cancer Ther; 11(11); 2541–6. ©2012 AACR.</jats:p> |
| doi_str_mv | 10.1158/1535-7163.mct-12-0358 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xNTM1LTcxNjMubWN0LTEyLTAzNTg |
| imprint | American Association for Cancer Research (AACR), 2012 |
| imprint_str_mv | American Association for Cancer Research (AACR), 2012 |
| institution | DE-D161, DE-Zwi2, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1 |
| issn | 1535-7163, 1538-8514 |
| issn_str_mv | 1535-7163, 1538-8514 |
| language | English |
| last_indexed | 2024-03-01T17:13:41.148Z |
| match_str | subbiah2012targetingtheapoptoticpathwayinchondrosarcomausingrecombinanthumanapo2ltraildulanerminadualproapoptoticreceptordr4dr5agonist |
| mega_collection | American Association for Cancer Research (AACR) (CrossRef) |
| physical | 2541-2546 |
| publishDate | 2012 |
| publishDateSort | 2012 |
| publisher | American Association for Cancer Research (AACR) |
| record_format | ai |
| recordtype | ai |
| series | Molecular Cancer Therapeutics |
| source_id | 49 |
| spelling | Subbiah, Vivek Brown, Robert E. Buryanek, Jamie Trent, Jonathan Ashkenazi, Avi Herbst, Roy Kurzrock, Razelle 1535-7163 1538-8514 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/1535-7163.mct-12-0358 <jats:title>Abstract</jats:title> <jats:p>Recombinant human Apo2L/TRAIL (dulanermin) is based on the ligand for death receptors (DR4 and DR5), which promotes apoptosis. We report a patient with refractory chondrosarcoma who showed a prolonged response to dulanermin and explore mechanisms of response and resistance. This heavily pretreated patient had progressive metastatic chondrosarcoma to the lung. On dulanermin (8 mg/kg i.v. on days 1–5 in a 21-day cycle), the patient achieved a sustained partial response with only subcentimeter nodules remaining. After 62 months of dulanermin treatment, progressive disease in the lungs was noted, and the patient underwent a resection that confirmed chondrosarcoma. DR4 was detected (immunohistochemistry) in the patient's tumor, which may have enabled the response. However, upregulation of prosurvival proteins, namely, phosphorylated (p)-NF-κBp65 (Ser 536), p-STAT3 (Tyr 705), p-ERK 1/2 (Thr 202/Tyr 204), p-mTOR (Ser 2448), FASN, and Bcl-2, were also detected, which may have provided the underlying mechanisms for acquired dulanermin resistance. The patient was restarted on dulanermin and has continued on this treatment for an additional 16 months since surgery (78 months since initiation of treatment), with his most recent computed tomography (CT) scans showing no evidence of disease. Mol Cancer Ther; 11(11); 2541–6. ©2012 AACR.</jats:p> Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist Molecular Cancer Therapeutics |
| spellingShingle | Subbiah, Vivek, Brown, Robert E., Buryanek, Jamie, Trent, Jonathan, Ashkenazi, Avi, Herbst, Roy, Kurzrock, Razelle, Molecular Cancer Therapeutics, Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist, Cancer Research, Oncology |
| title | Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist |
| title_full | Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist |
| title_fullStr | Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist |
| title_full_unstemmed | Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist |
| title_short | Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist |
| title_sort | targeting the apoptotic pathway in chondrosarcoma using recombinant human apo2l/trail (dulanermin), a dual proapoptotic receptor (dr4/dr5) agonist |
| title_unstemmed | Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1158/1535-7163.mct-12-0358 |